Wang QQ, Zhou L, Qin G, Tan C, Zhou YC, Yao SK. Leukocyte immunoglobulin-like receptor B2 overexpression as a promising therapeutic target and noninvasive screening biomarker for colorectal cancer. World J Gastroenterol 2023; 29(37): 5313-5326 [PMID: 37899785 DOI: 10.3748/wjg.v29.i37.5313]
Corresponding Author of This Article
Shu-Kun Yao, MD, PhD, Professor, Department of Gastroenterology, Peking University China-Japan Friendship School of Clinical Medicine, No. 2 Yinghua East Road, Chaoyang District, Beijing 100029, China. shukunyao@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Control Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Wang QQ, Zhou L, Qin G, Tan C, Zhou YC, Yao SK. Leukocyte immunoglobulin-like receptor B2 overexpression as a promising therapeutic target and noninvasive screening biomarker for colorectal cancer. World J Gastroenterol 2023; 29(37): 5313-5326 [PMID: 37899785 DOI: 10.3748/wjg.v29.i37.5313]
World J Gastroenterol. Oct 7, 2023; 29(37): 5313-5326 Published online Oct 7, 2023. doi: 10.3748/wjg.v29.i37.5313
Leukocyte immunoglobulin-like receptor B2 overexpression as a promising therapeutic target and noninvasive screening biomarker for colorectal cancer
Qian-Qian Wang, Lei Zhou, Geng Qin, Chang Tan, Yuan-Chen Zhou, Shu-Kun Yao
Qian-Qian Wang, Chang Tan, Yuan-Chen Zhou, Shu-Kun Yao, Department of Gastroenterology, Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China
Lei Zhou, Department of General Surgery, China-Japan Friendship Hospital, Beijing 100029, China
Geng Qin, Department of Gastroenterology, China-Japan Friendship Hospital, Beijing 100029, China
Author contributions: Wang QQ analyzed the data and drafted the manuscript; Tan C and Zhou YC collected samples and clinical data; Zhou L and Qin G provided guidance on experimental procedures; Yao SK supervised the study performance, revised the manuscript, and obtained the funding; and all authors read and approved the final manuscript.
Supported bythe National Key Development Plan for Precision Medicine Research, No. 2017YFC0910002.
Institutional review board statement: This study was approved by the Ethics Committee of China-Japan Friendship Hospital (No. 2018-116-K85).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shu-Kun Yao, MD, PhD, Professor, Department of Gastroenterology, Peking University China-Japan Friendship School of Clinical Medicine, No. 2 Yinghua East Road, Chaoyang District, Beijing 100029, China. shukunyao@126.com
Received: June 15, 2023 Peer-review started: June 15, 2023 First decision: August 26, 2023 Revised: September 8, 2023 Accepted: September 14, 2023 Article in press: September 14, 2023 Published online: October 7, 2023 Processing time: 102 Days and 2.1 Hours
Core Tip
Core Tip: Based on prior proteomic research rather than simple data mining, this study innovatively proposed and validated that leukocyte immunoglobulin-like receptor B2 (LILRB2) and its ligand, the angiopoietin-like protein 2 protein, are significantly overexpressed in colorectal cancer (CRC) and closely associated with tumour progression and a poor prognosis. In addition, this study is the first to propose that serum LILRB2 concentration can be used as a novel screening biomarker with a sensitivity of 89.74%, a specificity of 88.89% and an accuracy rate of 89.63% for the diagnosis of CRC. The sensitivity and accuracy were significantly higher than those of carcinoembryonic antigen and carbohydrate antigen 19-9. Therefore, LILRB2 could be a promising therapeutic target and noninvasive screening biomarker for CRC.
